Patient Square Capital’s Revolution Medicines RVMD Stock Holding History

Patient Square Capital’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$51.7M	Buy	+276,000	New	+$40.3M	8.01%	2

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Patient Square Capital's RVMD Position: Q2 2026 in Review

Patient Square Capital opened a new position in Revolution Medicines (RVMD) in Q2 2026: 276,000 shares worth $51.7M. The stake represents 8.01% of the portfolio and ranks #2 among its holdings.

688 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

Patient Square Capital held 276,000 shares of Revolution Medicines worth $51.7M as of Q2 2026.
Revolution Medicines was a new Patient Square Capital position in Q2 2026.
Revolution Medicines made up 8.01% of Patient Square Capital's portfolio in Q2 2026, its #2 holding.
688 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Patient Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.